- Home
- EOS vs QURE Comparison
EOS vs QURE Comparison
Compare EOS & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EOS | QURE |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2004 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EOS | QURE |
|---|---|---|
| Price | $22.05 | $46.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 132.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.44 | $8.73 |
| 52 Week High | $24.49 | $71.50 |
Technical Indicators
Market Signals| Indicator | EOS | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 64.12 |
| Support Level | $21.73 | $21.16 |
| Resistance Level | $22.27 | $50.47 |
| Average True Range (ATR) | 0.31 | 2.14 |
| MACD | 0.07 | 0.32 |
| Stochastic Oscillator | 76.62 | 99.80 |
Price Performance
Historical ComparisonAbout EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.